HELPERBY’S SOLUTION TO THE ANTIBIOTIC RESISTANCE CRISIS
Helperby has discovered and is developing a suite of Antibiotic Resistance Breakers (ARBs). These compounds, when combined with old antibiotics, can restore the original potency against both Gram positive and Gram negative bacteria. One of these combinations (ARB-002) is active against all three of the critical priority pathogens identified by the World Health Organisation.*
Helperby’s ARBs have unique mechanisms of action and differ from other antibiotics in clinical use. They are highly relevant to major commercially valuable markets & are covered internationally by extensive patents.
Two of Helperby’s ARBs are currently in development in six pre-clinical and clinical trials:
ARB-001
- Rapidly active against a wide range of key clinically important bacterial strains eg. MRSA and MSSA
- 99.9999% reduction in bacterial count in combination with several classes of existing antimicrobials against MRSA and Pseudomonas in vitro
- Low propensity for the induction of bacterial resistance
ARB-002
- In combination with low dose Colistin (last resort antibiotic), kills CRE (carbapenem-resistant Enterobacteriaceae) and Colistin resistant CRE
- In combination with low dose Colistin, active against carbapenem / Colistin sensitive and resistant Klebsiella, E.coli, Enterobacter and also against carbapenem-resistant / Colistin sensitive Pseudomonas and Acinetobacter
* Antibacterial Agents in Clinical Development, WHO 2017
SINGLE INTACT BACTERIUM
BACTERIUM AFTER HELPERBY TREATMENT
Antibiotic Renewables, A Technology For The Long Term?
All new antibiotics face the threat of resistance from increasingly smart bacteria. Using Helperby’s ARBs, it may be possible to renew old antibiotics over and over again for hundreds of years, rather like renewable energy:
- An old antibiotic is combined with a new ARB and is developed as a treatment for bacteria resistant to all other antibiotics
- Inevitably, within 20-30 years, resistance will arise to this combination so the same antibiotic is then combined with a new second ARB
- Again, resistance arises, so the same antibiotic is combined with a new third ARB
- And so on, again and again
This is the first potential long term renewable solution to the antibiotic crisis.
View the Helperby Therapeutics product pipeline
News
Key Papers